Parts Greater Than the Whole
This article was originally published in Start Up
Executive Summary
In a time when many small biotechs are consolidating, Desmos Inc. appears to be taking a contrarian position as it prepares to divide itself into two separately financed, stand-alone businesses. Desmos shareholders will soon hold shares in a new cell-therapy focused company as well as a tissue-engineering company.